The role of mirtazapine in patients with fibromyalgia: a systematic review

Abstract

Mirtazapine is commonly used to treat major depressive disorder. Due to its effects on multiple neurotransmitters, it has been investigated for possible benefits in patients with fibromyalgia. The objective of this systematic review is to assess the efficacy and safety of mirtazapine in the treatment of patients with fibromyalgia. Pubmed (1946-May 2018), Embase (1947-May 2018), CENTRAL, and ClinicalTrials.gov were queried using the search term combination: fibromyalgia, pain, chronic pain, neuralgia, neuropathic pain, chronic widespread pain, or chronic pain syndrome and mirtazapine. Studies appropriate to the objective were evaluated, including three randomized, placebo-controlled trials and one open-label trial, investigating the effect of mirtazapine in patients with fibromyalgia. In patients with fibromyalgia, treatment with mirtazapine resulted in improvements in pain, sleep, and quality of life. Study durations ranged from 6 to 13 weeks and studies used varying dosing strategies for mirtazapine. Minor occurrences of somnolence, weight gain, nasopharyngitis, dry mouth, and increased appetite were reported with mirtazapine use. Based on the reviewed literature, mirtazapine appears to be a promising therapy to improve pain, sleep, and quality of life in patients with fibromyalgia. These benefits were demonstrated in patients that were treatment naïve and those that had failed previous therapies. Additional clinical evidence through larger and longer length trials would be of benefit to further define the role of mirtazapine for patients with fibromyalgia.

This is a preview of subscription content, log in to check access.

Fig. 1

References

  1. 1.

    Mirtazapine tablets [package insert] (2016) Updated 2016. Mylan Pharmaceuticals Inc., Morgantown

  2. 2.

    Queiroz LP (2013) Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep 17:356

    Article  Google Scholar 

  3. 3.

    Kia S, Choy E (2017) Update on treatment guideline in fibromyalgia syndrome with focus on pharmacology. Biomedicines 5:E20

    Article  Google Scholar 

  4. 4.

    Clauw DJ (2014) Fibromyalgia: a clinical review. JAMA 311:1547–1555

    Article  Google Scholar 

  5. 5.

    Phillips K, Clauw DJ (2013) Central pain mechanisms in the rheumatic diseases: future directions. Arthritis Rheum 65:291–302

    Article  Google Scholar 

  6. 6.

    Kato K, Sullivan PF, Evengård B, Pedersen NL (2009) A population-based twin study of functional somatic syndromes. Psychol Med 39:497–505

    CAS  Article  Google Scholar 

  7. 7.

    Jahan F, Nanji K, Qidwai W, Qasim R (2012) Fibromyalgia syndrome: an overview of pathophysiology, diagnosis and management. Oman Med J 27:192–195

    Article  Google Scholar 

  8. 8.

    Wolfe F, Smythe HA, Yunus MB et al (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33:160–172

    CAS  Article  Google Scholar 

  9. 9.

    Wolfe F, Clauw DJ, Fitzcharles MA et al (2011) Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol 38:1113–1122

    Article  Google Scholar 

  10. 10.

    Wolfe F, Clauw DJ, Fitzcharles MA, at al (2016) Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 46:319–329

    Article  Google Scholar 

  11. 11.

    Macfarlane GJ, Kronisch C, Dean LE et al (2017) EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis 76:318–328

    CAS  Article  Google Scholar 

  12. 12.

    Higgins JPT, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. (updated March 2011). The Cochrane Collaboration. http://handbook.cochrane.org. Accessed 23 May 2018

  13. 13.

    Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269

    Article  Google Scholar 

  14. 14.

    Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12

    CAS  Article  Google Scholar 

  15. 15.

    Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73:712–716

    Article  Google Scholar 

  16. 16.

    Samborski W, Lezańska-Szpera M, Rybakowski JK (2004) Effects of antidepressant mirtazapine on fibromyalgia symptoms. Rocz Akad Med Bialymst 49:265–269

    CAS  PubMed  Google Scholar 

  17. 17.

    Yeephu S, Suthisisang C, Suttiruksa S, Prateepavanich P, Limampai P, Russell IJ (2013) Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. Ann Pharmacother 47:921–932

    Article  Google Scholar 

  18. 18.

    Miki K, Murakami M, Oka H, Onozawa K, Yoshida S, Osada K (2016) Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain 157:2089–2096

    CAS  Article  Google Scholar 

  19. 19.

    Suttiruksa S, Yeephu S, Prateepavanich P, Suthisisang C (2016) Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial. Asian Biomed 10:435–445

    CAS  Google Scholar 

  20. 20.

    Verbunt JA, Pernot DH, Smeets RJ (2008) Disability and quality of life in patients with fibromyalgia. Health Qual Life Outcomes 6:8

    Article  Google Scholar 

  21. 21.

    Theadom A, Cropley M, Humphrey KL (2007) Exploring the role of sleep and coping in quality of life in fibromyalgia. J Psychosom Res 62:145–151

    Article  Google Scholar 

  22. 22.

    Bigatti SM, Hernandez AM, Cronan TA, Rand KL (2008) Sleep disturbances in fibromyalgia syndrome: relationship to pain and depression. Arthritis Rheum 59:961–967

    Article  Google Scholar 

  23. 23.

    Lexi-Comp Online (2018) Lexi-Comp, Inc., Hudson, Ohio. Available at: http://online.lexi.com/. Accessed 19 Jan 2018

Download references

Funding

No external funding was secured for this review.

Author information

Affiliations

Authors

Contributions

All authors substantially contributed to the concept and design, acquisition of the data, or analysis and interpretation; drafting or revision of the manuscript for important intellectual content; and gave final approval for submission and publication.

Corresponding author

Correspondence to Andreina A. Ottman.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to disclose.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Financial disclosure

The authors report no financial relationships relevant to this article to disclose.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ottman, A.A., Warner, C.B. & Brown, J.N. The role of mirtazapine in patients with fibromyalgia: a systematic review. Rheumatol Int 38, 2217–2224 (2018). https://doi.org/10.1007/s00296-018-4068-3

Download citation

Keywords

  • Pain
  • Chronic pain
  • Fatigue
  • Sleep
  • Quality of life
  • Depression